ABBV Stock Recent News
ABBV LATEST HEADLINES
Many products sold by companies aren't must-have items. However, healthcare is a necessity.
You've probably heard this before: Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case?
Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with enterprise software sales or consumer goods, spending on healthcare tends to move in a positive direction regardless of what's happening to the overall economy.
This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to exceed $190 billion by 2028. Every year, regulatory agencies approve dozens of biosimilars and brand-name drugs, so Seeking Alpha readers should be careful when making decisions.
Inflation continues to erode purchasing power, and recent volatility highlights the uncertainty in inflation trends. Despite this, long-term investors can still find opportunities. In an unpredictable environment, focusing on companies with resilient business models can provide stability. Coca-Cola, AbbVie, and TC Energy stand out in this regard. These stocks offer defensive growth, attractive dividends, and strong fundamentals. They're well-positioned to navigate inflation while providing consistent income and long-term returns.
In the most recent trading session, AbbVie (ABBV) closed at $173.70, indicating a +1.37% shift from the previous trading day.
AbbVie Inc. (NYSE:ABBV ) J.P. Morgan 43rd Annual Healthcare Conference January 15, 2025 11:15 AM ET Company Participants Rob Michael - Chief Executive Officer Scott Reents - Executive Vice President, Chief Financial Officer Jeff Stewart - Executive Vice President, Chief Commercial Officer Roopal Thakkar - Executive Vice President, Research & Development, Chief Scientific Officer Conference Call Participants Chris Schott - J.P.
AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on Wednesday.
In December, I invested around $1,200 primarily in Business Development Companies, boosting my annual dividend income by $131 with a full-year total of almost $1,700.
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.